Characterisation of nicotine receptors on human peripheral blood mononuclear cells (PBMC) by Wongsriraksa, A. et al.
Characterisation of nicotine receptors on human peripheral blood mononuclear 
cells (PBMC) 
 
 
A.Wongsriraksa; M.E. Parsons; C.J. Whelan 
 
Department of Life Sciences, University of Hertfordshire, College Lane, Hatfield, Hertfordshire, 
AL10 9AB UK.  E mail c.j.whelan@herts.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correspondence to C.J. Whelan, e mail c.j.whelan@herts.ac.uk  
 
 
Running title nAChR on human PBMC 
 
 
Keywords:  Leukocyte, nicotine, receptor, human PBMC 
Abstract  
 
Aim and objective 
The aim of the work was to characterise the nAChRs on human PBMC.  
Method 
PBMC were isolated from human blood buffy coats provided by the blood transfusion service 
and were used for radioligand binding studies with [
3
H]-nicotine.  RT-PCR experiments were 
used to determine nAChR subunit expression while immunoblotting experiments were used to 
confirm that nAChR subunits identified by RT-PCR were translated into protein. 
Results 
Binding studies suggested the presence of one binding site for (-)- nicotine on human peripheral 
blood lymphocytes.  Competition studies showed that only (-)-nicotine, epibatidine and α-
bungarotoxin, displaced radiolabelled nicotine from cells. RT-PCR studies demonstrated mRNA 
for α4, α5, α7, β1and β2 nAChRs subunits in PBMC.  Expression of α5 mRNA subunit of 
nAChR was observed in all lymphocyte samples tested.  In contrast, the expression pattern of 
mRNAs for α4, α7, β1, and β2 mRNAs subunits of nAChRs, varied between samples. Western 
blot analysis showed that protein for α4, α5, and α7 and β2 nAChR subunits was expressed in 
most, but not all of the PBMC samples tested but some of the bands obtained were faint.   
Conclusion 
The results obtained suggest that human PBMC contain nAChRs containing α4β2, α4β2α5, 
and/or α7 subunits. 
 
 Introduction 
 
We, and others, have previously shown that nicotine inhibits TNBS-induced colitis in rats [1, 2].  
We have also shown that nicotine, at concentrations likely to be found in the blood of tobacco 
users [3] suppresses TNF release from a monocytic cell line (THP-1 cells) [2].  In addition, 
nicotine has a small inhibitory effect on TNF-induced IL-8 release from an epithelial cell line 
(HT-29) [4].  Furthermore, the inhibitory effect of nicotine on IL-8 release appeared to be 
mediated by 7 homomeric nicotinic acetylcholine receptors (nAChR), in that the inhibitory 
effect of nicotine on HT-29 cells was blocked by an antagonist of the 7 nAChR, -
bungarotoxin.  In addition, RT-PCR and western blotting experiments demonstrated the presence 
of mRNA and protein for this receptor in HT-29 cells [4]. 
 
A criticism of the above work is that many of the in vitro studies were conducted using artificial 
cell lines and the data may not be relevant to man.  Lymphocytes are key cells in inflammatory 
responses and modulation of their function by nAChR agonists, including nicotine derived from 
the use of tobacco, represents a potential target for therapeutic intervention as well as an 
explanation for tobacco-induced disorders.  Published work has shown that nicotine and nAChR 
ligands suppress lymphocyte proliferation [5], modulate cytokine release [6, 7] or increase T 
cell-mediated cytotoxicity [8].  However, the identity of the receptor(s) mediating these effects is 
not clear with some studies claiming they are mediated by non-cholinergic nicotine receptors [9] 
while others provide evidence for a nAChR mediated effect [10].  Furthermore, there is no 
consensus as to the composition of the nAChR on human lymphocytes with some studies 
demonstrating expression of nAChR subunits that were not identified by others [11, 12,13].  
Collectively, this work suggests the presence of functional receptors for nicotine on PBMC and 
these observations have led to the proposal that the 7 nAChR is a potential therapeutic target 
[14,15].  However, the therapeutic potential of ligands for the 7 nAChR depends on the 
contribution made by other nAChR receptor subtypes to the effects of nicotine. 
 
One explanation for these findings may be that a genetic variation leads to variability in nAChR 
expression on human PBMC.  Alternatively, different findings may result from the different 
endpoints measured in different studies.  In view of the significance of these data to the 
therapeutic potential of nAChR, we decided to characterise nAChR on human PBMC using a 
combination of radioligand binding, RT-PCR and western blotting in an attempt to resolve these 
discrepancies. 
 
Method 
 
Materials 
Buffy coat cells were obtained from the National Blood Transfusion Service (NBTS; Colindale, 
UK).  These cells were a by-product of blood processed for clinical use and no details as to 
tobacco use or ethnicity were provided.  [
3
H]-nicotine was purchased from NEN Life Sciences, 
(Zaventum, Belgium). RNA STAT-60
TM
 kit for RNA extraction was purchased from Biogenesis, 
(Poole, UK), reagents for RT-PCR were purchased as a kit (Access RT-PCR ) from Promega 
(Southampton, UK).  Primers for RT-PCR were obtained from Invitrogen Life Technologies 
(Paisley, UK) and brain RNA from Origene Technologies Inc., (Cambridge, UK).  Antibodies 
for the 4, 5 and 2 nAChR subunits were purchased from Covance Research Products 
(Berkley, CA.,USA) and the antibody for the 7 nAChR subunit from Research Diagnostics Inc. 
(Flanders, NJ., USA).  Histopaque 1077, Aprotinin, Leupeptin and PBS-tween 20 were 
purchased from Sigma-Aldrich (Poole, UK).  
 
Isolation of PBMC 
On receipt, buffy coats were diluted with phosphate buffered saline (PBS) to a total leukocyte 
count of 1 x 10
7
 cells/ml.  Aliquots (25ml) of this suspension were layered over an equal volume 
of histopaque 1077.  Gradients were subjected to centrifugation (1000 x g for 25 min at room 
temperature) and PBMC were recovered from the PBS/histopaque interface.  Finally, PBMC 
were washed with PBS and resuspended in Hanks balanced salt solution (5mM KCl; 0.5mM 
KH2PO4; 0.13 mM NaCl; 0.3 mM Na2PO4; 5mM glucose; 20mM HEPES and 1mM EDTA) at a 
density of 1 x 10
7
 cells/ml. 
 
Radioligand binding studies 
Radioligand binding studies were performed on intact PBMC as described previously for THP-1 
cells [16].  Briefly, for saturation studies PBMC were incubated with [
3
H]-nicotine (0.9 x 10
-9
 M 
to 4 x 10
-8
 M) at 4°C for 50 minutes.  For competition experiments, a single concentration of 
[
3
H]-nicotine (1.5 x 10
-8
 M) was used.  In experiments where association and dissociation times 
were determined, a concentration of 2.0 x 10
-8
 M [
3
H]-nicotine was used and the incubation time 
varied between 1 and 120 minutes.  Non-specific binding was determined by the addition of an 
excess of unlabelled nicotine (1 x 10
-5
 M).  Incubations were terminated by filtration of the cells 
in a cell harvester (Skatron) followed by washing with 5ml ice cold HBSS.  The [
3
H]-nicotine 
content of each filter was determined by liquid scintillation counting. 
 
Isolation of total RNA and RT-PCR  
 
Total RNA was extracted from PBMC using a single-step protocol (RNA STAT-60
TM
).  RNA 
was extracted from PBMC homogenates by the addition of 20% v/v chloroform followed by 
centrifugation at 12000 x g for 15 min at 4°C.  The colourless upper aqueous phase was 
harvested and mixed with 0.5 volume of isopropanol and the RNA precipitate collected by 
centrifugation (12000 x g, 1 hr, 4°C).  After washing twice with cold ethanol, by centrifugation 
at 7500 x g for 45 mins at, 4°C, the RNA was subjected to RT-PCR.  RNA concentration and 
quality were assessed based on 260 nm/280 nm absorbance ratios.  
 
RT-PCR experiments were conducted using a commercially available kit.  Human PBMC RNA 
was used as an experimental template and human brain RNA was used as a positive control.  
Primer pairs for nAChR subunits (1-7, 10, 1 and 4) were designed as described 
previously [4] and were obtained commercially.   
 
Each primer (final concentration 1µM) was mixed with total RNA (final concentration 1µg) and 
subjected to RT-PCR.  A protocol where, for the first strand cDNA synthesis, 1 cycle at 48ºC for 
45 minutes (reverse transcription), and 1 cycle at 94ºC for 2 minutes (AMV RT-inactivation, 
RNA/cDNA/primer denaturation) was used.  For the second strand synthesis and PCR 
amplification, a further 35 cycles at 94ºC for 30 seconds (denaturation), 55º C for 1 minute 
(annealing), and an extension step at 68º C for 2 minutes.  The final extension was for 1 cycle at 
68º C for 7 minutes, and the last 1 cycle at 4º C (soak). 
 
Following RT-PCR, aliquots of the reaction mixture were subjected to electrophoresis on 
agarose (1.5%) at a constant voltage (50V) for 3h in a TAE buffer (Tris base 0.04M; 0.0.001M 
EDTA; pH 8.0 with glacial acetic acid).  The size of PCR products was estimated by comparison 
of bands with DNA molecular weight markers (New England, BioLabs Inc., Hitchin, UK) used 
as a reference in each gel.   
 Immunoblotting 
Human PBMC (1 x 10
7
 cells) were suspended in 0.5 ml of cell lysis buffer (125 mM Tris HCl, 
pH 6.8; 2% w/v sodium dodecyl sulphate; 10% v/v glycerol) containing aprotinin (60g/ml; 
Sigma) and leupeptin (10 g/ml; Sigma) as described by Laemmli [17].  Cells were incubated on 
ice for 5 mins followed by incubation at 95°C for 5-10 mins to reduce the viscosity of the lysate.  
Following centrifugation at 14000 x g, for 10 min at room temperature, the lysate (supernatant) 
was recovered and the protein concentration of determined. 
 
Rat brain protein was used as a positive control and was prepared according to a protocol 
provided by Pharmingen Ltd., (B.D.Biosciences UK, 2003).  Briefly, brains were homogenised 
in 50mM Tris/HCl buffer (pH 7.4) containing 10% w/v sucrose, 5mM EDTA, leupeptin (10 
g/ml) and aprotinin (60 g/ml).  Following centrifugation (800 x g, 4°C, 20 min), pellets were 
resuspended in sucrose (320 mM) and rehomogenised.  The resulting homogenate was 
centrifuged (16000 x g, 4°C, 30 min).  This process was repeated, the pellet suspended in Tris/ 
acetate buffer (pH 7.4) and the protein concentration determined.   
 
Protein samples were subjected to SDS-PAGE electrophoresis in a discontinuous Tris/glycine 
buffer as described by Laemmli [17].  Stacking and resolving gels contained 5 and 10% SDS-
PAGE respectively.  Protein samples (20g/well) were added and gels subjected to 
electrophoresis at 200V for 30-40 min at room temperature.  Following electrophoresis, gels 
were either stained with Coomassie brilliant blue to identify protein bands or transferred to a 
blotting buffer sandwich for transfer to nitrocellulose membranes and immunoblotting.  
Electrophoretic transfer of protein from acrylamide gels to nitrocellulose membranes was 
performed as described by Tobin et al., [18].   
 
Following transfer of proteins to nitrocellulose membranes, membranes were blocked by 
immersion for 2h at room temperature in 5% w/v semi-skimmed milk (Marvell, Cadbury, UK) in 
PBS containing 0.05% Tween 20 (Sigma UK).  Membranes were then incubated with 
monoclonal antibodies for nAChR subunits overnight at 4°C.  The final dilution of monoclonal 
antibodies used was 1:1000 for anti-4 nAChR antibody and 1:500 for anti-5, anti-7 and anti-
2 nAChR antibodies.  Following washing with PBS-tween 20 (4 x 5 min), membranes were 
incubated with goat anti-rat IgG horseradish peroxidase (dilution 1:5,000) (for experiments with 
4, 5 and 2 nAChR subunits) or goat anti-mouse IgG horseradish peroxidase (for experiments 
with 7 nAChR subunits) (dilution 1:5,000) for 2h.  Immunoreactivity was detected using the 
enhanced chemiluminescence (ELC) system (Amersham Life Sciences, UK). 
 
Statistical analysis 
Data obtained from radioligand binding studies were analysed using commercially available 
software (Prism, Graphpad, San Diego, USA).  Data were analysed using a non-linear curve 
fitting procedure and all values were derived from this analysis.  Values quoted represent the 
mean ± s.e.mean of the number of observations stated.  Kd and IC50 values were determined 
from each individual experiment and the values stated represent the mean and standard error of 
the number of replicate experiments conducted. 
Results 
 
Isolation of PBMC 
The number of lymphocytes recovered from a sample of blood differed from donor to donor and 
was dependent, to an extent, on the initial volume of the buffy coat provided.  However, usually 
30 x 10
7
 cells were recovered from a single buffy coat giving 30 ml of cell suspension when 
suspended at a concentration of 1 x 10
7
 cells/ml.  All lymphocyte cell suspensions used in these 
experiments had viability >95 % as determined by trypan blue exclusion tests.  The lymphocyte 
purity was >99% as determined from staining cytospin preparations followed by a differential 
count under oil immersion. 
 
Radioligand binding  
Preliminary experiments showed that [
3
H]-(-)-nicotine bound to PBMC at 4˚C.  The half time of 
association was 12.02 ± 5.15 minutes and binding reached equilibrium after 25 minutes.  
However, considerable intersubject variation was experienced and specific binding of [
3
H]-(-)-
nicotine was usually low and was <30% of total binding in most experiments. 
 
[
3
H]-(-)-nicotine (0.9 x 10
-9
M - 4.0 x 10
-8
M) bound to PBMC in a concentration-related manner 
and was saturable (Figure 1).  From these data the presence of a single binding site for nicotine 
was identified on human lymphocytes with a Kd of 15.00 ± 5.76 nM (1.5 ± 0.58 x 10
-8
M) and a 
Bmax of 2253 ± 409.00 sites/cell. 
 
In competition binding experiments using a single concentration of [
3
H]-(-)-nicotine (1.5 x 10
-
8
M), a number of compounds such as (-) - nicotine, α-bungarotoxin, cytisine, d-tubocurarine, 
epibatidine, hexamethonium, atropine, and carbachol were used to investigate the nature of 
nicotine binding sites on human lymphocytes.  Of these, only nicotine, epibatidine (IC50 = 10.48 
± 2.14 nM, n=5) and α-bungarotoxin (IC50 = 13.30 ± 2.83 nM, n=5) competed with [
3
H]-(-)-
nicotine for the binding site on PBMC (Figure 2) while cytosine, d-tubocurarine, 
hexamethonium, atropine and carbachol did not consistently displace [
3
H]-(-)-nicotine in a 
concentration-related manner (data not shown).   
 
RT-PCR 
Following electrophoresis and ethidium bromide staining, in each experiment a PCR product was 
observed with a molecular size that corresponded to the predicted size of the PCR product if 
nAChR subunit mRNA was present in the human PBMC.  The predicted size of these products 
was 190 bp for α1, 349 bp for α2, 474 bp for α3, 387 bp for α4, 556 bp for α5, 356 bp for α6, 451 
bp for α7, 589 bp for β1, 309 bp for β2, 418 for β3, and 220 bp for β4.  All human PBMC tested 
expressed mRNA for α4, α5, and β1, nAChR.  No mRNA for α1, α2, α3, α6, α10, β3 or β4 
nAChR subunits was detected in any of the samples studied (Table 2).  The expression of mRNA 
for α7 (present in 8 out of 10), and β2 (5 out of 10), nAChR subunits was not seen in all samples 
(Table 1).  The presence or absence of mRNA for these subunits did not appear to correlate with 
blood group (Table 1). 
 
Immunoblotting 
When human PBMC protein was subjected to SDS-PAGE electrophoresis and stained with 
Coomassie Brilliant Blue, a range of protein bands were detected with molecular sizes from 10 to 
250 kD.  Rat brain protein (the positive control) also showed the same range of protein bands as 
human lymphocytes.   
 
However, not all PBMC samples tested appeared to express the same nAChR subunits.  Human 
PBMC expressed proteins with immunoreactivity suggesting the presence of α4 (70 kD), α5 (53 
kD), α7 (56 kD), and β2 (57 kD) nAChR subunit protein (Table 2).  Protein bands for α7 nAChR 
protein subunits were detected with a molecular size of 56 kD in all samples tested.  However, 
the bands varied in intensity from subject to subject (Figure 3) although, in many of these 
experiments, the band for the positive control (rat brain protein) was also less distinct than that 
obtained for other nAChR subunits. 
 
Expression of β2 nAChR protein subunits was detected in 6 out of the 12 samples tested but the 
observed bands were faint. (Table 2).   
Discussion 
 
The aim of the present study was to extend previous findings from our laboratory, and those 
published by others [10, 11, 12, 13], by characterising the nAChR on human PBMC.  In 
attempting to do so we found that there were relatively few nAChR on these cells, as suggested 
by low specific binding of radiolabelled nicotine, and that the nature of this binding was subject 
to intersubject variation, a finding that was not explicitly suggested by some previously 
published work[12, 19].  Since further purification of cells into lymphocyte subsets would have 
reduced the number of cells obtained to a level where radioligand binding studies would have 
been impractical.  Thus, these studies were performed on cells that were a mixture of lymphocyte 
subsets (PBMC).  In order to be consistent, RT-PCR and immunoblotting experiments were also 
performed on cells purified to the same extent. 
 
Initial studies utilised radioligand binding in order to identify the number of binding sites for 
nicotine on PBMC.  Preliminary experiments revealed that non-specific binding of [
3
H]-nicotine 
comprised a high percentage of the total binding and that this was reduced if whole cells were 
used rather than using cell membrane preparations.  This high degree of non-specific binding has 
been reported by others [16, 20, 21] and may reflect the lipophilic nature of nicotine.  In spite of 
the high degree of non-specific binding the data obtained from kinetic experiments indicate that 
nicotine interacts with a single binding site.  Furthermore, binding of nicotine to PBMC occurs at 
concentrations of nicotine likely to be encountered in the blood of tobacco users [3] suggesting 
that this binding may be clinically relevant.   
 
Competition studies showed that binding of [
3
H]-nicotine was substantially reversed by 
epibatidine and -bungarotoxin suggesting that the binding site for [3H]-nicotine was a nAChR, 
eliminating the possibility that PBMC used in the samples studied contained a non-cholinergic 
nicotine receptor as reported by others [9].  -bungarotoxin is a ligand which binds preferentially 
to the 7-homomeric nAChR [22, 23].  Epibatidine also has an affinity for nAChR containing 
4, and 7 subunits [24, 25].  Thus, it is possible that human PBMC contain a mixture of these 
two nAChR subtypes although the low specific binding and intersubject variabilty did not enable 
a definitive identification to be made.  Others have also studied the nicotine receptors on human 
PBMC [20, 21, 26, 27] although no consensus is apparent. One group found a number of nicotine 
binding sites in PBMC but the [
3
H] nicotine-binding site was not saturable [20].  Many groups 
have reported data suggesting the presence of the 7 homomeric nAChR [28, 29].  It has also 
been reported that d-tubocurarine (a nAChR antagonist) inhibited radiolabeled ACh binding by 
lymphocytes suggesting that the receptor present on PBMC contained α7 nAChR subunits [30].  
These findings conflict with those obtained in the present study although the relatively poor 
affinity of d-tubocurarine for the 7nAChR [31], coupled with the high degree of non-specific 
binding experienced in the present study, may have rendered competition difficult to detect.  
Furthermore, others, [12, 32] identified 4 nAChR subunits in human circulating lymphocytes 
from healthy volunteers, a finding confirmed by in situ hybridisation in one study [32].  However 
in a study of lymphocytes from 7 subjects, Sato et al [11] did not find expression of this nAChR 
subunit.  Many of these earlier studies did not report the degree of intersubject variability seen in 
the present study with regard to expression of  nAChR subunits but one group [11, 13] did find 
intersubject variation in 2 nAChR subunit expression. 
 
The source of this intersubject variability is of importance in order to understand the therapeutic 
potential of selective nAChR agonists.  Such variability may result from induction of nAChR 
subunit expression in smokers compared to non-smokers as has been noted in leukocytes [18, 
33].  Alternatively, the variability may be genetic in origin and linked to some other factor.  
Clearly it would be preferable to conduct experiments on PBMC taken from subjects whose 
background was known, particularly with regard to tobacco exposure but the source of PBMC 
used, and the volume of blood required for radioligand binding studies, precluded this in the 
present study.  However, the blood cells used in the present study were provided by NBTS 
whose primary purpose is to provide blood products for clinical use and the smoking status of 
donors is not gathered at the time of donation.  
 
In an attempt to further characterise the nAChR present on PBMC, and to understand the 
intersubject variability observed, we used molecular biology to determine nAChR subunit 
expression at the gene and protein level.  Thus, RNA from PBMC was analysed to see if a wide 
range of nAChR subunits were expressed and membrane protein examined by immunoblotting to 
see which of the nAChR subunits, identified by ligand binding and RT-PCR were present in the 
cell membrane.  In the present study, of the 10 subjects, all expressed mRNA for the 1 nAChR 
and half the subjects also expressed mRNA for 2 nAChR.  However, expression of the 2 
nAChR subunit appeared to be low since only faint bands were seen in some, but not all, samples 
examined by Western blotting, a finding described previously by others [12].  These findings 
differ from those published by some groups in which lymphocytes also expressed mRNA for the 
2 nAChR subunit but did not express the 1 subunit [11].  In contrast, work published by others 
failed to find mRNA for the 2, 1 or the 2 nAChR subunit [34, 35] although Benhammou et 
al. reported expression of mRNA and protein for 4 and 2 nAChR in human blood 
leukocytes[12].   
 
There are many possible explanations for these observations and further work may be necessary 
to determine the reason for these differences.  Because the presence of nAChRs containing 1 
subunits was not suggested by the radioligand binding data, and no mRNA for the 1 nAChR 
was detected, we elected not to immunoblot gels for this subunit since this subunit was unlikely 
to form a functional receptor.  The majority of subjects expressed mRNA and protein for 7 
nAChR subunits suggesting the presence of the 7 homomeric nAChR on human PBMC, a 
finding that is supported by the radioligand binding data and confirms previously published work 
[28].  In addition, mRNA for 4 and 5 nAChR was detected by RT-PCR in most of the subjects 
studied and also appears to result in expression of subunit protein.  Thus, the most likely 
explanation for our findings is that PBMC from most subjects express 7 nAChR but that many 
subjects also express other receptors such as the 4β2 and α452 nAChR.  Although this work 
was based on a limited number of blood samples the variation in nAChR seen may correlate with 
blood group, suggesting a genetic basis for the intersubject variation seen.  However, further 
studies with blood samples taken from a greater number of donors, with a known history is 
required to confirm this hypothesis. 
 
The findings of the present study are consistent with those of others who have used molecular 
biology to study nAChR on PBMC [11, 12, 28, 29, 32] although few reports have mentioned the 
intersubject variability observed in the present study [11, 28], possibly because cells were 
harvested from a relatively small number of subjects.  In studies where samples from a limited 
number of subjects was used the investigators may have inadvertently selected samples that were 
similar in composition and responded similarly to nicotine [19].  In contrast, in other studies [11, 
28,] a more diverse group of subjects may have been selected and the intersubject variation was 
apparent. 
 
It has been proposed that acetylcholine receptors on leukocytes have a physiological role [13].  
Lymphocytes, and other cells, are able to synthesise acetylcholine [13] which is released and can 
modify T and B cell activity [36].  While it is possible that such processes may modulate 
lymphocyte activity in situations where cells are in close proximity to each other, it is also 
possible that nicotine and nAChR ligands may modulate lymphocyte activity.  Thus, nAChR 
ligands may have both therapeutic potential as well as the potential to promote pathologies that 
result from immune cell malfunction. 
 
In conclusion, the experiments described above show that human PBMC, taken from a wide 
range of subjects, possess nicotine receptors that bind nicotine in a manner consistent with the 
presence of a nAChR.  Furthermore, this receptor also binds epibatidine and -bungarotoxin 
suggesting the presence of 7 homomeric nAChR or/and α4β2 nAChR.  However, RT-PCR and 
immunoblotting experiments using PBMC from a number of subjects revealed a degree of 
intersubject variation that may impact on the therapeutic utility of nAChR ligands. 
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 Figure 1. Saturation binding of [
3
H]-(-)-nicotine to human lymphocytes.  The graph shows 
specific binding of [
3
H]-(-)-nicotine to human lymphocytes.  The results were obtained from a 
filtration assay conducted at 4 ºC for 50 minutes.  Data represented are the mean ± SEM of 5 
experiments and each experiment was performed in triplicate.  The Bmax of binding site was 
2253 ± 409 sites/cells and Kd was 15.00 ± 5.76 nM (1.5 ± 0.58 x 10
-8
M). 
 
Figure 2.  Competition binding of [
3
H]-(-)-nicotine to human lymphocytes by A unlabeled-(-)-
Nicotine, B epibatidine and C -bungarotoxin.  Cells were incubated with 15 nM (1.50 x 10-8M) 
[
3
H]-(-)-nicotine in the presence of a serial dilution of (-)-nicotine for 35 minutes, at 4ºC.  Each 
chart is a single experiment in graphical form.  Each point is the mean of a single concentration 
of drug performed in triplicate.  
 
Figure 3. Western blot analysis of 12 samples of human lymphocyte protein was screened for the 
presence of nAChR α7 subunit protein using a monoclonal antibody against the α7 nAChR 
subunit.  Lanes 1-12 were loaded with 20 g of human PBMC protein.  In all samples, a band of 
the appropriate size was identified and the protein products were visualised by ELC. M = Perfect 
Protein HRP Western Makers (Novagen, Nottingham, UK), R = rat brain protein membrane, 
Lanes 1-12 = human lymphocytes (← = predicted molecular weight). 
Table 1.  The expression of mRNAs encoding nicotinic acetylcholine receptor subunits in human 
peripheral blood lymphocytes.  The predicted products were observed by 1.5 % agarose gel 
electrophoresis.  (+) = mRNA for subunit present in human lymphocytes, (-) = mRNA for 
subunit was not detected in human lymphocytes, (+/-) = mRNA for subunit was detected, but the 
product bands were faint. 
 
Table 2.  Individual nAChR subunit profiles determined by Western blotting of 12 human PBMC 
protein samples.  Each lane was loaded with 20 g of protein.  Samples were tested for subunits 
where mRNA expression was detected by RT-PCR experiments.  (+) = Protein detected; (-) = no 
protein detected; (+/-) = faint expression detected. 
 
 
 
